JW Pharmaceutical Holds Symposium for Hematology-Oncology Specialists

"Continuing Academic Communication with Medical Professionals"

JW Pharmaceutical announced on the 16th that it held the "FANTASY Symposium" for hematology-oncology medical staff at Oakwood Premier COEX Center in Gangnam-gu, Seoul, for two days starting from the 11th.

The FANTASY Symposium is an integrated academic event organized to share the latest research data and real-world clinical experiences with JW Pharmaceutical's treatments: Tavalisse for immune thrombocytopenia (ITP), Actemra for immune diseases, and Ferinject, a high-dose intravenous iron injection.

JW Pharmaceutical held the "FANTASY Symposium" for hematology-oncology medical staff over two days starting on the 11th at Oakwood Premier COEX Center in Gangnam-gu, Seoul. JW Pharmaceutical

On the first day of the symposium, Professor Jeong Jongheon from the National Cancer Center highlighted the unique mechanism of action of Tavalisse, which fundamentally suppresses platelet destruction caused by autoantibodies. He also shared the efficacy and safety data of Tavalisse observed in global and Japanese Phase 3 clinical trials.

Professor Kwon Jihyun from Chungbuk National University Hospital presented multinational real-world data, as well as a case in which a domestic patient—previously unresponsive to multiple drug therapies—maintained stable platelet counts in a "long-term treatment-free remission" after discontinuing Tavalisse monotherapy.

On the second day, Professor Choi Taeho from Samsung Medical Center delivered a lecture on "Intravenous Iron Therapy in Patients with Cancer-Induced Anemia (CIA)." Professor Lee Hyunjung from Kyung Hee University Medical Center introduced Actemra as an effective therapy for cytokine release syndrome (CRS), which can occur during CAR-T cell and bispecific antibody cancer treatments.

JW Pharmaceutical plans to continue academic exchanges based on treatment guidelines and clinical data for each product and expand the sharing of treatment strategies and medical information that can be referenced in various medical settings.

A company representative stated, "We will continue to provide a wide range of medical information related to Tavalisse, Ferinject, and Actemra, and maintain active academic communication with medical professionals."

This content was produced with the assistance of AI translation services.